Spark Therapeutics — J.P. Morgan Healthcare Conference 2016
23 slides from Spark Therapeutics's conference presentation, Jan 11, 2016

Slide 1: Spark Therapeutics, Inc. J.P. Morgan Healthcare Conference
Spark Therapeutics, Inc. J.P. Morgan Healthcare Conference January 11, 2016 Exhibit 99.1

Slide 2: Forward-looking statements
Forward-looking statements This presentation includes ‘‘forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation

Slide 3: First gene therapy platform validated by successful randomized, controlled pivotal trial
First gene therapy platform validated by successful randomized, controlled pivotal trial of SPK-RPE65 (voretigene neparvovec) Phase 3 data statistically and clinically significant for RPE65-mediated blindness with >3 years of durability data from comparable Phase 1 cohort Expect to complete BLA fili

Slide 4: Spark's platform has yielded clinical candidates and the first successful Phase 3 trial in field
Spark’s platform has yielded 3 clinical candidates and the first successful randomized, controlled pivotal Phase 3 trial in field Inherited retinal dystrophies (IRDs) Liver-associated disease (Liver) Neuro-degenerative diseases (CNS) SPK-RPE65 (RPE65-mediated IRDs) SPK-CHM (Choroideremia) SPK-FIX (H

Slide 5: Expect to file new INDs in 2016 with data readouts across 3 franchises by 1H17
Expect to file 2 new INDs in 2016 with data readouts from 5 clinical programs across 3 therapeutic franchises by 1H17 IRDs Liver SPK-RPE65 (RPE65-mediated IRDs) SPK-CHM (Choroideremia) SPK-FIX (Hemophilia B) CNS SPK-FVIII (Hemophilia A) SPK-TPP1 (TPP1 deficiency, a form of Batten disease) Proven Vec

Slide 6: Between 2017 and 2018, platform should consist of total clinical programs
Between 2017 and 2018, platform should consist of 10 total clinical programs, including 5 new INDs IRDs Liver CNS SPK-FVIII (Hemophilia A) Huntington’s disease Leber hereditary optic neuropathy RhoNova (RHO-adRP) Orphan Orphan Orphan Non-orphan SPK-TPP1 (TPP1 deficiency, a form of Batten disease) SP

Slide 7: Optimizing portfolio: internal innovation, commercialization, partnering and collaboration
RhoNova (RHO-adRP) Optimizing portfolio: From internal innovation and commercialization to partnering, acquisition and collaboration IRDs Liver SPK-FIX (Hemophilia B) CNS SPK-FVIII (Hemophilia A) Non-orphan SPK-RPE65 (RPE65-mediated IRDs) SPK-CHM (Choroideremia) SPK-TPP1 (TPP1 deficiency, a form of

Slide 8: Spark aims to deliver commercial or pivotal-stage programs from 10 clinical programs by 2018
RhoNova (RHO-adRP) Spark aims to deliver 3 commercial or pivotal-stage programs from 10 clinical programs by 2018 IRDs Liver CNS SPK-FIX (Hemophilia B) SPK-FVIII (Hemophilia A) Non-orphan SPK-RPE65 (RPE65-mediated IRDs) SPK-CHM (Choroideremia) SPK-TPP1 (TPP1 deficiency, a form of Batten disease) Hun

Slide 9: SPK-RPE65: Statistically and clinically significant results for RPE65-mediated IRDs
SPK-RPE65: Statistically and clinically significant results for RPE65-mediated IRDs

Slide 10: Phase 3 results statistically and clinically significant
Phase 3 results statistically and clinically significant 65% of intervention subjects (no controls) passed at 1 lux at year one, demonstrating maximum improvement measurable 100-fold improvement in light sensitivity, on average, in subjects receiving SPK-RPE65 Mean Full-Field Light Sensitivity (301

Slide 11: Restoring functional vision through one-time administration of SPK-RPE65
Restoring functional vision through one-time administration of SPK-RPE65 CH-41: baseline visit at 4 lux (Fail) CH-41: 1-year visit after SPK-RPE65 administration at 4 lux (Pass) Note: The videos of CH-41 are representative of the mean improvement demonstrated in the intervention group in the Phase 3

Slide 12: Further visual acuity analyses demonstrate statistical significance
Further visual acuity (VA) analyses demonstrate statistical significance Using the Lange scale, intervention subjects demonstrated a 9 letter average improvement vs. 1.6 for controls (p = 0.047) In a subgroup analysis recommended by our DSMB where subjects that developed cataracts (n = 3) are remove

Slide 13: Phase 3 data following durability of effect pattern similar to Phase 1 cohort
Phase 3 data following durability of effect pattern similar to Phase 1 study cohort on both MT and FST Abbreviation: BL = baseline, MT = mobility test mITT population for 301 study. Intervals are +/- one standard error Mean MT: lux score/level, bilateral (mITT) – 301 trial lux score/level, injected

Slide 14: Spark positioned to file BLA for SPK-RPE65 in 2H16, and MAA in early 2017
Spark positioned to file BLA for SPK-RPE65 in the second half of 2016, and MAA in early 2017 SPK-RPE65 is uniquely positioned as the first therapeutic for RPE65-mediated IRDs Regulatory Progress 10 years of collaboration with FDA on program including 2011 Advisory Committee prior to Phase 3 trial in

Slide 15: SPK-RPE65: At the forefront of shaping a patient-centric commercial model
SPK-RPE65: At the forefront of shaping a patient-centric, commercial model for gene therapies Market Size Estimated prevalent population: 3,500 prevalent in US and EU5 with additional patients in EU23, Latin America and Asia Spark’s investments in genetic testing for IRDs and stakeholder education w

Slide 16: 2016 clinical pipeline: current programs and new INDs
2016 clinical pipeline: 2 current programs and 2 new INDs

Slide 17: SPK-CHM leverages SPK-RPE65 with initial efficacy data expected in 2H16
SPK-CHM leverages SPK-RPE65 with initial efficacy data expected in 2H16 and Phase 3 trial start anticipated in 2017 Choroideremia affects an estimated 12,500 males in the US and EU5, or ~3.5x the SPK-RPE65 population Currently enrolling 2nd dose cohort in Phase 1/2 trial First dose cohort (n = 5) an

Slide 18: SPK-FIX in collaboration with Pfizer for hemophilia B: What makes it different?
SPK-FIX in collaboration with Pfizer for the treatment of hemophilia B: What makes it different? Novel bioengineered capsid may increase addressable patient population Initial efficacy data from Phase 1/2 trial expected mid-2016 Single-stranded, codon optimized cassette may yield more homogeneous, p

Slide 19: SPK-FVIII for hemophilia A: Leverages Spark expertise and SPK-FIX experience
SPK-FVIII for hemophilia A: Leverages Spark expertise and SPK-FIX experience Expect to file an IND in 2H16 with initial efficacy data in 1H17 Low dose Mid dose High dose Source: Spark data presented at ASH, December 2015. Source: Spark data presented at ASH, December 2015. Source: Spark data present

Slide 20: SPK-TPP1: Proprietary approach for AAV gene therapy delivery to the brain
SPK-TPP1: Establishing a proprietary approach for AAV gene therapy delivery to the brain TPP1 deficiency is a fatal neurodegenerative disease affecting children with an estimated prevalence of 1000 and incidence of 100 annually in US and EU5 Source: Katz M et al., Science Translational Medicine 2015

Slide 21: SPK-TPP1 demonstrated potential to delay onset and progression in TPP1 deficiency model
SPK-TPP1 demonstrated potential to delay onset and progression in a well-established model of TPP1 deficiency TPP1 deficient untreated dog (Porthos) at 9.7 months of age Treated dog (McCartney) at 17.5 months Expect to file an IND in the 2H16 with initial efficacy data in the 1H17, creating the pote

Slide 22: A platform capable of generating a number of near-term catalysts
A platform capable of generating a number of near-term catalysts

Slide 23: Significant number of data readouts and regulatory milestones expected over the next 18 months
Significant number of data readouts and regulatory milestones expected across 5 clinical candidates over the next 18 months SPK-CHM (Choroideremia) SPK-FIX (Hemophilia B) SPK-FVIII (Hemophilia A) SPK-TPP1 (TPP1 deficiency, a form of Batten disease) Phase 3 visual acuity (VA) data 302 trial readout (
Source: SEC EDGAR · 8-K filed Jan 11, 2016


